EP4168027A4 - Verfahren und zusammensetzungen zur behandlung von chemotherapieinduzierter diarrhö - Google Patents

Verfahren und zusammensetzungen zur behandlung von chemotherapieinduzierter diarrhö

Info

Publication number
EP4168027A4
EP4168027A4 EP20940856.6A EP20940856A EP4168027A4 EP 4168027 A4 EP4168027 A4 EP 4168027A4 EP 20940856 A EP20940856 A EP 20940856A EP 4168027 A4 EP4168027 A4 EP 4168027A4
Authority
EP
European Patent Office
Prior art keywords
compositions
methods
induced diarrhea
treating chemotherapy
chemotherapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP20940856.6A
Other languages
English (en)
French (fr)
Other versions
EP4168027A1 (de
Inventor
Lisa A Conte
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Napo Pharmaceuticals Inc
Original Assignee
Napo Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Napo Pharmaceuticals Inc filed Critical Napo Pharmaceuticals Inc
Publication of EP4168027A1 publication Critical patent/EP4168027A1/de
Publication of EP4168027A4 publication Critical patent/EP4168027A4/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP20940856.6A 2020-06-19 2020-06-19 Verfahren und zusammensetzungen zur behandlung von chemotherapieinduzierter diarrhö Pending EP4168027A4 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2020/038691 WO2021257089A1 (en) 2020-06-19 2020-06-19 Methods and compositions for treating chemotherapy-induced diarrhea

Publications (2)

Publication Number Publication Date
EP4168027A1 EP4168027A1 (de) 2023-04-26
EP4168027A4 true EP4168027A4 (de) 2024-04-03

Family

ID=79268234

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20940856.6A Pending EP4168027A4 (de) 2020-06-19 2020-06-19 Verfahren und zusammensetzungen zur behandlung von chemotherapieinduzierter diarrhö

Country Status (10)

Country Link
EP (1) EP4168027A4 (de)
JP (1) JP2023538186A (de)
KR (1) KR20230027226A (de)
AU (1) AU2020454132A1 (de)
BR (1) BR112022025741A2 (de)
CA (1) CA3182864A1 (de)
IL (1) IL299028A (de)
JO (1) JOP20220339A1 (de)
MX (1) MX2022016367A (de)
WO (1) WO2021257089A1 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115089592B (zh) * 2022-05-21 2024-02-27 复旦大学 多重酪氨酸激酶在制备抑制肠道病毒71型嗜神经性病毒药物中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120202876A1 (en) * 2009-10-06 2012-08-09 Napo Pharmaceuticals, Inc. Methods of treating diseases with proanthocyanidin oligomers such as crofelemer
WO2016112312A1 (en) * 2015-01-09 2016-07-14 Jaguar Animal Health Methods of treating diarrhea in companion animals

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013010774A2 (pt) * 2010-10-31 2017-03-21 Napo Pharmaceuticals Inc "usos de crofelemer no tratamento de diarreia associada ao hiv"
US20160067311A1 (en) * 2014-09-10 2016-03-10 Helsinn Healthcare Sa Use of elsiglutide to treat gastrointestinal mucositis including chemotherapy-induced diarrhea
AU2017370682A1 (en) * 2016-12-06 2019-06-20 Kaleido Biosciences, Inc. Glycan polymers and related methods thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120202876A1 (en) * 2009-10-06 2012-08-09 Napo Pharmaceuticals, Inc. Methods of treating diseases with proanthocyanidin oligomers such as crofelemer
WO2016112312A1 (en) * 2015-01-09 2016-07-14 Jaguar Animal Health Methods of treating diarrhea in companion animals

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"Abstracts of the MASCC/ISOO Annual Meeting 2018 ED - Olver Ian", SUPPORTIVE CARE IN CANCER, SPRINGER BERLIN HEIDELBERG, BERLIN/HEIDELBERG, vol. 26, no. Suppl 2, 23 April 2018 (2018-04-23), pages 39 - 364, XP037066669, ISSN: 0941-4355, [retrieved on 20180423], DOI: 10.1007/S00520-018-4193-2 *
GAO JENNIFER J. ET AL: "HALT-D: A Phase II Evaluation of Crofelemer for the Prevention and Prophylaxis of Diarrhea in Patients With Breast Cancer on Pertuzumab-Based Regimens", CLINICAL BREAST CANCER, vol. 17, no. 1, 1 February 2017 (2017-02-01), US, pages 76 - 78, XP055889027, ISSN: 1526-8209, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5896289/pdf/nihms955198.pdf> DOI: 10.1016/j.clbc.2016.08.005 *
See also references of WO2021257089A1 *

Also Published As

Publication number Publication date
AU2020454132A1 (en) 2023-02-02
JOP20220339A1 (ar) 2023-01-30
MX2022016367A (es) 2023-01-30
KR20230027226A (ko) 2023-02-27
BR112022025741A2 (pt) 2023-01-03
JP2023538186A (ja) 2023-09-07
WO2021257089A1 (en) 2021-12-23
EP4168027A1 (de) 2023-04-26
IL299028A (en) 2023-02-01
CA3182864A1 (en) 2021-12-23

Similar Documents

Publication Publication Date Title
ZA202207394B (en) Compositions and methods for treating hemoglobinopathies
EP4136254A4 (de) Ace2-gerichtete zusammensetzungen und verfahren zur behandlung von covid-19
IL285886A (en) Preparations and methods for the treatment of laminopathy
EP3965832A4 (de) Zusammensetzungen und verfahren zur behandlung von hepatitis b
EP4096675A4 (de) Zusammensetzungen und verfahren zur behandlung von long covid
IL285796A (en) Methods and preparations for the treatment of cancer
EP4168027A4 (de) Verfahren und zusammensetzungen zur behandlung von chemotherapieinduzierter diarrhö
EP4110822A4 (de) Zusammensetzungen und verfahren zur behandlung von krebs
EP4127722A4 (de) Verfahren und zusammensetzungen zur behandlung von krebs
EP4125835A4 (de) Verfahren und zusammensetzungen zur behandlung oder prävention von entzündlichen zuständen
EP4157304A4 (de) Formulierungen und verfahren zur behandlung von diarrhö
IL307872A (en) New compositions and methods for the treatment of corona virus infections
EP4157260A4 (de) Zusammensetzungen und verfahren zur behandlung von kopfschmerzen
EP4149450A4 (de) Zusammensetzungen und verfahren zum härten
EP4114438A4 (de) Verfahren und zusammensetzungen zur behandlung von muskelatrophie
EP4103192A4 (de) Zusammensetzungen und verfahren zur behandlung von coronavirusinfektionen
EP4121451A4 (de) Zusammensetzungen und verfahren zur behandlung von lupus
EP4135760A4 (de) Zusammensetzungen und verfahren zur behandlung von leukämie
EP4100430A4 (de) Zusammensetzungen und verfahren zum behandeln von pulmonaler hypertonie
EP4069253A4 (de) Methoden und zusammensetzungen zum behandeln von glioblastom
EP3894564A4 (de) Verfahren und zusammensetzungen zur behandlung von hyperoxalurie
IL304462A (en) The composition includes a cannabinoid for the treatment of bladder problems
EP4154001A4 (de) Verfahren und zusammensetzungen zur behandlung von schlaganfall
IL305806A (en) Compounds and methods for the treatment of polycythemia
GB202211117D0 (en) Compositions and methods for non-immunogenecity

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20230104

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230519

DAV Request for validation of the european patent (deleted)
RAX Requested extension states of the european patent have changed

Extension state: BA

Payment date: 20230104

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40092051

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20240305

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 1/12 20060101ALI20240228BHEP

Ipc: A61K 31/353 20060101ALI20240228BHEP

Ipc: A61K 36/47 20060101AFI20240228BHEP